ReviewGeneral psychiatry2022
Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder.
Review in General psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Association between digital smart device use and depression among older adults: systematic review and meta-analysis.BMC public health · 2026Pooled it
- Pro-dopaminergic pharmacological interventions for anhedonia in depression: a living systematic review and network meta-analysis of human and animal studies.EBioMedicine · 2025Pooled it
- Efficacy ofWorld journal of psychiatry · 2025Trial
- EEG Unpredictability in the Resting State of Major Depressive Disorder: A Multidomain EEG Analysis.Brain topography · 2026Article
- Anticipatory pleasure as a key hedonic component in classifying major depressive disorder: multidimensional behavioral evidence from majority vote algorithm.BMC psychiatry · 2026Article
- Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.Neuropsychiatric disease and treatment · 2026Article
- The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures.EXCLI journal · 2026Review
- Article
- Transdiagnostic links of reward processing in obsessive-compulsive disorder and depression.Journal of affective disorders · 2025Article
- Exploring pleasure as a mediator of outcomes in music therapy.BMC complementary medicine and therapies · 2025Article
- Leveraging stacked classifiers for exploring the role of hedonic processing between major depressive disorder and schizophrenia.Psychological medicine · 2025Article
- Understanding anhedonia in major depressive disorder in Japan: epidemiology and unmet needs from patients' and physicians' perspectives.BMC psychiatry · 2025Observational
- Brain connectivity and transcriptional changes induced by rTMS in first-episode major depressive disorder.Translational psychiatry · 2025Article
- Establishing content validity of the Dimensional Anhedonia Rating Scale.Journal of patient-reported outcomes · 2025Article
- Article
- Efficacy of dynamic interpersonal therapy in improving mentalising in patients with major depressive disorder and the mediating effect of mentalising on changes in depressive symptoms.General psychiatry · 2025Article
- Optogenetics and chemogenetics: key tools for modulating neural circuits in rodent models of depression.Frontiers in neural circuits · 2025Review
- Quantitative scale validation of the Dimensional Anhedonia Rating Scale in the treatment of Chinese patients with major depressive disorder.General psychiatry · 2025Article
- High rates of mood disorders in patients with chronic idiopathic eosinopenia.Brain, behavior, & immunity - health · 2024Article
- Mapping of the network connection between sleep quality symptoms, depression, generalized anxiety, and burnout in the general population of Peru and El Salvador.Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increasing heavy disease burden of major depressive disorder (MDD) globally. Both high diagnostic heterogeneity and complicated pathological mechanisms of MDD pose significant challenges. There is much evidence to support anhedonia as a core feature of MDD. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, anhedonia is further emphasised as a key item in the diagnosis of major depression with melancholic features. Anhedonia is a multifaceted symptom that includes deficits in various aspects of reward processing, such as anticipatory anhedonia, consummatory anhedonia, and decision-making anhedonia. Anhedonia is expected to become an important clinicopathological sign for predicting the treatment outcome of MDD and assisting clinical decision making. However, the precise neurobiological mechanisms of anhedonia in MDD are not clearly understood. In this paper, we reviewed (1) the current understanding of the link between anhedonia and MDD; (2) the biological basis of the pathological mechanism of anhedonia in MDD; and (3) challenges in research on the pathological mechanisms of anhedonia in MDD. A more in-depth understanding of anhedonia associated with MDD will improve the diagnosis, prediction, and treatment of patients with MDD in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.